Patents Assigned to GemVax AS
-
Publication number: 20150099692Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.Type: ApplicationFiled: May 7, 2013Publication date: April 9, 2015Applicants: KAEL-GEMBAX CO., LTD., GEMVAX ASInventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
-
Patent number: 8614177Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described.Type: GrantFiled: January 3, 2011Date of Patent: December 24, 2013Assignee: Gemvax ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Moller, Marianne Klemp Gjertsen, Ingvil Saeterdal
-
Publication number: 20120269858Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.Type: ApplicationFiled: May 31, 2012Publication date: October 25, 2012Applicant: GEMVAX ASInventors: Gustav GAUDERNACK, Stein SÆBØE-LARSSEN, Mona MØLLER, Jon Amund ERIKSEN
-
Patent number: 8193326Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognizing and destroying tumor cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.Type: GrantFiled: March 5, 2008Date of Patent: June 5, 2012Assignee: GemVax ASInventors: Gustav Gaudernack, Stein Sæbøe-Larssen, Mona Møller, Jon Amund Eriksen
-
Publication number: 20110105721Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described.Type: ApplicationFiled: January 3, 2011Publication date: May 5, 2011Applicant: GEMVAX ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal
-
Patent number: 7863244Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.Type: GrantFiled: August 3, 2006Date of Patent: January 4, 2011Assignee: Gemvax ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal
-
Patent number: 7794723Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.Type: GrantFiled: January 17, 2006Date of Patent: September 14, 2010Assignee: GemVax ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal, Stein Sæbøe-Larsen
-
Patent number: 7375117Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognizing and destroying tumor cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.Type: GrantFiled: March 29, 2006Date of Patent: May 20, 2008Assignee: GemVax ASInventors: Gustav Gaudernack, Stein Sæøe-Larssen, Mona Møller, Jon Amund Eriksen
-
Patent number: 7192927Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.Type: GrantFiled: February 12, 2004Date of Patent: March 20, 2007Assignee: Gemvax ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Moller, Marianne Klemp Gjertsen, Ingvil Saeterdal
-
Publication number: 20070004632Abstract: Peptides from cancer related protein products of frameshift mutated genes which eliciting T cellular immunity for use in cancer vaccines and compositions for anticancer treatment.Type: ApplicationFiled: August 3, 2006Publication date: January 4, 2007Applicant: GEMVAX ASInventors: Gustav Gaudernack, Jon Eriksen, Mona Moller, Marianne Gjertsen, Ingvil Saeterdal
-
Publication number: 20060194731Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.Type: ApplicationFiled: March 29, 2006Publication date: August 31, 2006Applicant: GemVax AsInventors: Gustav Gaudernack, Stein Saeboe-Larssen, Mona Moller, Jon Eriksen
-
Patent number: 7078416Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.Type: GrantFiled: December 18, 2001Date of Patent: July 18, 2006Assignee: GemVax ASInventors: Gustav Gaudernack, Stein Sæbøe-Larssen, Mona Møller, Jon Amund Eriksen
-
Publication number: 20060106196Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.Type: ApplicationFiled: January 17, 2006Publication date: May 18, 2006Applicant: GemVax ASInventors: Gustav Gaudernack, Jon Eriksen, Mona Moller, Marianne Gjertsen, Ingvil Saeterdal, Stein Saeboe-Larsen
-
Patent number: 7030211Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.Type: GrantFiled: June 30, 1990Date of Patent: April 18, 2006Assignee: GemVax ASInventors: Gustay Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal, Stein Sæbøe-Larsen
-
Publication number: 20050074849Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.Type: ApplicationFiled: February 12, 2004Publication date: April 7, 2005Applicant: GEMVAX ASInventors: Gustav Gaudernack, Jon Eriksen, Mona Moller, Marianne Gjertsen, Ingvil Saeterdal
-
Patent number: 6861057Abstract: Frameshift Mutants ?-Amyloid precursor peptides and mutant ubiquitin-B associated with Alzheimer's disease and Down syndrome eliciting T cellular immunity for use in compositions for the treatment and/or prophylaxis of Alzheimer's disease and/or Down syndrome.Type: GrantFiled: April 30, 1999Date of Patent: March 1, 2005Assignee: GemVax ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller
-
Patent number: 6759046Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.Type: GrantFiled: June 4, 2001Date of Patent: July 6, 2004Assignee: Gemvax ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal